This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Avadel Pharmaceuticals (AVDL) Aktievy
Avadel Pharmaceuticals plc är verksamt som ett biofarmaceutiskt företag i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
AVDL Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Avadel Pharmaceuticals plc Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$21.64 |
| 52 veckors högsta | US$23.57 |
| 52 veckors lägsta | US$6.38 |
| Beta | 0 |
| 1 månads förändring | 0.74% |
| 3 månaders förändring | -8.15% |
| 1 års förändring | 151.34% |
| 3 års förändring | n/a |
| 5 års förändring | n/a |
| Förändring sedan börsintroduktionen | 27.29% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Feb 03
AVDL: Revised Acquisition Terms And CVR Structure Will Shape Future Risk Balance
Analysts lifted their price target on Avadel Pharmaceuticals to $22.50 from $20, citing improved acquisition terms and updated deal expectations as the key reasons for the change. Analyst Commentary Recent research highlights how the evolving acquisition proposals around Avadel Pharmaceuticals are shaping valuation views and risk assessments for investors following the stock.
Uppdatering av berättelse • Jan 20
AVDL: Alkermes Cash Deal And CVR Structure Will Define Limited Upside
Analysts lifted their fair value estimate for Avadel Pharmaceuticals to $18.50 from $16.00, citing updated acquisition terms, improved contingent value right economics, and revised assumptions around margins and future P/E multiples following recent Street research. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has shifted toward a more balanced and, in several cases, more cautious stance as the Alkermes acquisition framework has taken shape.
Uppdatering av berättelse • Jan 06
AVDL: Cash Deal Terms And CVR Outcome Will Shape Future Returns
Analysts kept their fair value estimate for Avadel Pharmaceuticals at $23.00 per share while adjusting key assumptions, citing the updated Alkermes and Lundbeck proposals and evolving views on Lumryz royalties and contingent value right terms as the main drivers of the new target range around recent Street marks near $20.00 to $22.50. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has centered on the competing acquisition proposals from Alkermes and Lundbeck, as well as the value of Lumryz royalties and the contingent value right, or CVR, tied to potential future approvals.Uppdatering av berättelse • Dec 19
AVDL: Cash Deal And Contingent Payout Will Shape Future Returns
Analysts have trimmed their price target on Avadel Pharmaceuticals to $23.00 from about $31.47, reflecting updated assumptions for slightly higher risk, stronger revenue growth, and sharply improved profitability metrics in light of the evolving Alkermes acquisition dynamics and Lumryz-driven cash flow profile. Analyst Commentary Across recent research notes, bullish analysts acknowledge that headline price targets for Avadel are now clustered in the high teens to low twenties, reflecting the proposed acquisition by Alkermes and the embedded value of the contingent value right tied to Lumryz milestones.Recent updates
Uppdatering av berättelse • Feb 03
AVDL: Revised Acquisition Terms And CVR Structure Will Shape Future Risk Balance
Analysts lifted their price target on Avadel Pharmaceuticals to $22.50 from $20, citing improved acquisition terms and updated deal expectations as the key reasons for the change. Analyst Commentary Recent research highlights how the evolving acquisition proposals around Avadel Pharmaceuticals are shaping valuation views and risk assessments for investors following the stock.Uppdatering av berättelse • Jan 20
AVDL: Alkermes Cash Deal And CVR Structure Will Define Limited Upside
Analysts lifted their fair value estimate for Avadel Pharmaceuticals to $18.50 from $16.00, citing updated acquisition terms, improved contingent value right economics, and revised assumptions around margins and future P/E multiples following recent Street research. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has shifted toward a more balanced and, in several cases, more cautious stance as the Alkermes acquisition framework has taken shape.Uppdatering av berättelse • Jan 06
AVDL: Cash Deal Terms And CVR Outcome Will Shape Future Returns
Analysts kept their fair value estimate for Avadel Pharmaceuticals at $23.00 per share while adjusting key assumptions, citing the updated Alkermes and Lundbeck proposals and evolving views on Lumryz royalties and contingent value right terms as the main drivers of the new target range around recent Street marks near $20.00 to $22.50. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has centered on the competing acquisition proposals from Alkermes and Lundbeck, as well as the value of Lumryz royalties and the contingent value right, or CVR, tied to potential future approvals.Uppdatering av berättelse • Dec 19
AVDL: Cash Deal And Contingent Payout Will Shape Future Returns
Analysts have trimmed their price target on Avadel Pharmaceuticals to $23.00 from about $31.47, reflecting updated assumptions for slightly higher risk, stronger revenue growth, and sharply improved profitability metrics in light of the evolving Alkermes acquisition dynamics and Lumryz-driven cash flow profile. Analyst Commentary Across recent research notes, bullish analysts acknowledge that headline price targets for Avadel are now clustered in the high teens to low twenties, reflecting the proposed acquisition by Alkermes and the embedded value of the contingent value right tied to Lumryz milestones.Uppdatering av berättelse • Dec 05
AVDL: Acquisition And CVR Milestones Will Define Balanced Risk Reward Profile
Analysts have nudged our fair value estimate for Avadel Pharmaceuticals slightly lower, from $21.06 to $20.94 per share, as they balance modestly reduced long term multiple assumptions with the evolving acquisition landscape and contingent value right dynamics highlighted in recent research. Analyst Commentary Street research reflects a more balanced, wait and see stance on Avadel as the Alkermes transaction and competing interest from Lundbeck reshape the risk reward profile.Uppdatering av berättelse • Nov 21
AVDL: Competing Acquisition Proposals Will Shape Outcomes Amid Industry Uncertainty
Analysts have raised their fair value estimate for Avadel Pharmaceuticals from $19.13 to $21.06 per share. They cite improving profit margins and stronger near-term acquisition prospects as key factors behind the upward revision.Uppdatering av berättelse • Nov 05
AVDL: Future Acquisition to Reshape Sleep Disorder Market Amid Shifting Competitive Risks
Analysts have lowered their price target for Avadel Pharmaceuticals from $20.90 to $19.13 per share. This change reflects recent acquisition agreements and shifting perspectives on the company’s long-term growth prospects.Seeking Alpha • Oct 23
Avadel Settles With Jazz Pharmaceuticals, Gets Acquired By Alkermes
Summary Avadel Pharmaceuticals plc settled all disputes with Jazz Pharmaceuticals plc, paving the way for its acquisition by Alkermes plc for up to $20/share. The settlement grants AVDL $90 million in cash, freedom to operate globally with Lumryz, and eliminates a significant legal overhang. ALKS benefits from immediate earnings accretion, revenue diversification, and a strengthened position in sleep disorder treatments with Lumryz. JAZZ avoids billion-dollar-plus damages, secures modest royalties on Lumryz, and delays competition in idiopathic hypersomnia until 2028. Read the full article on Seeking AlphaUppdatering av berättelse • Oct 22
Analysts Adjust Avadel Pharmaceuticals Price Target Amid Acquisition and Ongoing Market Developments
Analysts have lowered their price target for Avadel Pharmaceuticals to $20 from previous higher levels. They cite the pending acquisition by Alkermes at $18.50 per share, plus a potential $1.50 contingent cash right, as the primary driver behind the adjustment.Uppdatering av berättelse • Oct 08
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts have raised their price target for Avadel Pharmaceuticals from $20.30 to $20.90, citing continued commercial momentum for Lumryz. However, they note this optimism is tempered by competitive and market uncertainties.Uppdatering av berättelse • Sep 23
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts marginally raised Avadel Pharmaceuticals’ price target to $20.30, citing strong commercial execution and growing Lumryz adoption, while noting competitive risks may limit upside. Analyst Commentary Bullish analysts highlight that commercial investments are delivering tangible benefits, evidenced by improved persistency and an expanding number of reimbursed Lumryz patients.Uppdatering av berättelse • Sep 08
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts have raised Avadel Pharmaceuticals' fair value target from $19.00 to $20.20, citing improved commercial execution for Lumryz and pipeline expansion opportunities, though some caution over competition and valuation is noted. Analyst Commentary Bullish analysts highlight commercial execution gains, with improved persistency trends and increasing reimbursed Lumryz patient counts driving revenue upside.Uppdatering av berättelse • Aug 24
Rising Awareness Of Sleep Disorders Will Drive Future Demand
The upward revision in Avadel Pharmaceuticals' consensus price target reflects improved revenue growth expectations and a modest increase in future P/E, resulting in a new fair value estimate of $19.12. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and projected Q3 2025 net product revenue of $71–$75 million.Analysartikel • Aug 10
Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates
NasdaqGM:AVDL 1 Year Share Price vs Fair Value Explore Avadel Pharmaceuticals's Fair Values from the Community and...Uppdatering av berättelse • Aug 09
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Despite a notable reduction in consensus revenue growth forecasts, the analyst price target for Avadel Pharmaceuticals has increased slightly to $18.00. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and expects Q3 net product revenue of $71–$75 million.Analysartikel • Aug 02
A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb
Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) shareholders have had their patience rewarded with a 26% share price jump in...Analysartikel • Jun 10
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Ny berättelse • May 04
LUMRYZ And REVITALYZ Trials Will Unlock Future Value
LUMRYZ's strong market penetration and $1 billion opportunity hint at future revenue growth, with competitive advantage over peers.Analysartikel • May 04
Market Participants Recognise Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Revenues Pushing Shares 28% Higher
Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Feb 11
Avadel Pharmaceuticals: Moving To A Speculative Buy
Summary Avadel Pharmaceuticals' primary asset, LUMRYZ, treats narcolepsy and is in Phase 3 trials for Idiopathic Hypersomnia, with significant revenue growth potential. Recent news includes the resignation of the Chief Commercial Officer, strong Q4 revenue growth, and a push from ASL Strategic Value Fund for strategic alternatives. Analysts are universally positive, with multiple Buy ratings and price targets ranging from $12 to $22, despite some downward revisions. Avadel has a solid balance sheet, no long-term debt, and insiders are accumulating shares, making it a speculative buy with potential for a profitable buyout. Read the full article on Seeking AlphaAnalysartikel • Feb 07
The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 26%
Unfortunately for some shareholders, the Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) share price has dived 26% in the...Analysartikel • Jan 13
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Dec 01
The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%
The Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Nov 22
Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Summary Avadel Pharmaceuticals plc's Lumryz, a superior alternative to Jazz's Xyrem, faces legal hurdles and market challenges despite winning key lawsuits and FDA approval. Financially, Avadel has a market cap of $1.04bn, $65.8mn cash, and increasing revenue, but high SG&A expenses and a weak cash position. Jazz's legal actions and the shrinking narcolepsy market limit Lumryz's revenue potential, raising concerns about Avadel's long-term viability. Despite supporting Avadel as a company, I recommend avoiding AVDL stock due to significant risks and financial challenges. Read the full article on Seeking AlphaAnalysartikel • Oct 16
Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable
When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales...Analysartikel • Sep 10
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Sep 03
Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Summary Avadel shareholders have enjoyed impressive gains of approximately 77% since my last article, reflecting positive developments in the company's performance. The article provides a comprehensive review of Avadel's progress and how it is faring against Jazz Pharmaceuticals in the oxybate market. Despite its lack of a conventional pipeline, the peak sales potential of LUMRYZ in its approved indication supports a speculative Buy rating for Avadel stock. Read the full article on Seeking AlphaSeeking Alpha • Jun 16
Avadel Pharmaceuticals: Inflection Point Ahead
Summary Avadel Pharmaceuticals is a small-cap biopharma company headquartered in Dublin, Ireland. The company's primary asset is LUMRYZ, which has the potential to be a 'best of breed' compound in a large market. Currently, Avadel is locked in a pivotal litigation battle with Jazz Pharmaceuticals, which it looks more and more likely to prevail. This sets up a potential key inflection point for the company and its shareholders. An updated analysis around Avadel Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Apr 02
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Summary Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel's ability to navigate challenges. We maintain a buy rating moving into 2024. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Summary Avadel's stock rose 51% post-buy recommendation, buoyed by Q4 earnings and a favorable royalty rate judgment versus Jazz Pharmaceuticals. Lumryz's market penetration and unique once-nightly dosing advantage are driving optimistic revenue forecasts and operational breakeven projections. A court ruling on the patent dispute awarded Avadel a manageable 3.5% royalty to Jazz, significantly less than the feared 27%. Recommends buying AVDL due to its strategic market position, financial health, and recent legal victory, despite high cash burn and ongoing litigation risks. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Summary Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential for Lumryz to be pulled from the market. Lumryz can capture a significant portion of the narcolepsy market and expand into idiopathic hypersomnia. Risk-reward looks favorable for the long side, although the tail legal risk should not be neglected, even if Jazz's attempts look desperate. Read the full article on Seeking AlphaAnalysartikel • Jan 16
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Jan 11
Avadel May Continue To Outperform With Positive Launch Momentum
Summary Avadel Pharma's launch of its product LUMRYZ is expected to drive the company's stock performance. LUMRYZ appears to have momentum and is differentiated from current narcolepsy treatments. The potential revenue for Avadel from LUMRYZ could ultimately range from $500 million to $2 billion, depending on market share and expansion into new indications. If things continue to go well, that might drive the share price beyond current levels on a multi-year view, but execution risks do remain. Read the full article on Seeking AlphaAnalysartikel • Sep 22
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aktieägarnas avkastning
| AVDL | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | -0.2% | 1.9% | -0.8% |
| 1Y | 151.3% | 41.8% | 27.1% |
Avkastning vs industri: AVDL översteg US Pharmaceuticals branschen som gav 41.8 % under det senaste året.
Avkastning vs Marknaden: AVDL översteg US marknaden som gav 27.1 % under det senaste året.
Prisvolatilitet
| AVDL volatility | |
|---|---|
| AVDL Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: AVDL har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: AVDL s veckovolatilitet ( 2% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2015 | 188 | n/a | www.avadel.com |
Avadel Pharmaceuticals plc är verksamt som ett biofarmaceutiskt företag i USA. Bolagets ledande produktkandidat är LUMRYZ, en formulering av natriumoxibat, som befinner sig i en klinisk fas 3-studie för behandling av kataplexi eller överdriven sömnighet under dagtid hos patienter sju år och äldre med narkolepsi. Bolaget var tidigare känt som Flamel Technologies SA och bytte namn till Avadel Pharmaceuticals plc i januari 2017.
Avadel Pharmaceuticals plc Sammanfattning av grunderna
| AVDL grundläggande statistik | |
|---|---|
| Börsvärde | US$2.12b |
| Vinst(TTM) | -US$278.00k |
| Intäkter(TTM) | US$248.52m |
8.5x
P/S-förhållande-7,640x
P/E-förhållandeÄr AVDL övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| AVDL resultaträkning (TTM) | |
|---|---|
| Intäkter | US$248.52m |
| Kostnad för intäkter | US$12.64m |
| Bruttovinst | US$235.88m |
| Övriga kostnader | US$236.16m |
| Intäkter | -US$278.00k |
Senast redovisade vinst
Sep 30, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.0028 |
| Bruttomarginal | 94.91% |
| Nettovinstmarginal | -0.11% |
| Skuld/egenkapitalförhållande | 35.5% |
Hur har AVDL utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/02/14 15:44 |
| Aktiekurs vid dagens slut | 2026/02/11 00:00 |
| Intäkter | 2025/09/30 |
| Årlig intjäning | 2024/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Avadel Pharmaceuticals plc bevakas av 8 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| James Molloy | Brean Capital Historical (Janney Montgomery) |
| Jason Butler | Citizens JMP Securities, LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |